To Question of Estimation of Secretory and Proliferative Activity of GH-Secreting Adenoma

Mykytyuk M.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Aim. To estimate secretory and proliferative activity of isolated somatotropinoma (ST) and somato- mammotropinoma (SMT). Materials and methods. We studied 133 patients (88 women and 45 man) (aged 44. 0 ± 12. 5 years old) with ac- romegaly (95 – with ST and 38 – with SMT). Term of disease was from 1 to 38 years. Disease activity was evaluated according to the Consensus Conference criteria (2000). To estimated age of patient, age of patient in manifestation of acromegaly (agemanifest.), duration of period before diagnosis (DPD) and duration of disease (DD). To elevated a total secretory activity of adenoma (TSA) (ng/ml), secretory activity of unit of adenoma (SAUPA) (ng/ml/sm3) and speed of tumor growth (STG) (sm3/years). The volume of hypophysis (VG) was calculated using the formula, which refers to G. Di Chiro and K. B. Nelson, 1962. To data are given as X ± s and nonlinear regression model equations parameters. The miсroadenomа in manifestation of acromegaly is verified only in 3,2 % patients, macroadenoma – in 92,2 %, giant adenoma – in 4,9 %. In 0,74 % patients found empty sella turcica. In a general group the VG was associated, as with agemanifest. (r = -0,41; P = 0,006), so with GH (r = 0,37; P = 0,046). The group SMT VG more higher, than in a group ST (Me 5,21 and 2,42 sm3, accordingly) (P = 0,002) and associated with GH (r = 0,53; P = 0,03), but not with PRL. The VG in a general group is associated with TSA (r = 0,38; P = 0,004), STG (r = 0,82; P < 0,00001) and SAUPA (r = -0,36; P = 0,006). The TSA in a general group is associated with STG (r = -0,36; P = 0,008) and SAUPA (r = 0,54; P < 0,0001). It is discovered association between STG and SAUPA (r = 0,56; P < 0,0001). It is set that in a group SMT SSA more higher, than in a group ST (Me 28,9[1,2-144,9] and Me 12,5[0,5-837,0] ng/ml, accordingly) (P = 0,02). The VG is associated with SSA both in a group ST (r = 0,54; P = 0,0006) and in a group SMT (r = 0,47; P = 0,04). SAUPA in groups ST and SMT did not differ, however VG is associated with SAUPA in both groups ((r = -0,54; P = 0,0007) and (r = -0,75; P = 0,0002), accordingly). In a group SMT the VG is associated with PRL (r = 0,79; P < 0,00001), which determines 63,4 % his dispersion, in that time as a GH only 22,1 %. In a group SMT VG is as- sociated with SAUPA was calculated using the PRL (r = 0,8; P < 0,00001). Correlation between STG and GH and STG and insulin-like growth factor-1 specifies on synchronousness of proliferative and secretory activity of growth hormone (GH)-secreting adenoma, and to reverse correlation between STG and SAUPA (rs = -0,41, P = 0,003) – connection is possible between the changes of receptor pattern of GH- secreting adenoma and it proliferative activity. Agemanifest. is modulated on secretory and proliferative activity of GH-secreting adenoma. The increase of VG in patients with acromegaly is accompanied the changes of specific specialization of GH-secreting adenoma, what leads prevailing of proliferative potential above secretory. The presence of association between the clinical flow of acromegaly and secretory and proliferative activity of GH-secreting adenoma, in particular connection between «aggressive» clinical flow a SMT with their high secretory and proliferative activity. It is set that considerable duration of DPD and DD is inherent the of high «benign» clinical flow of acromegaly at in relation to low TSA, to «malignant» – insignificant DPD and DD at high TSA of GH-secreting pituitary adenoma.

acromegaly, growth hormone, prolactin, secretory activity of pituitary adenoma, proliferatory activ- ity of pituitary adenoma

• Определение объема гипофиза по данным сагиттальных сечений при низкопольной магнитно-резонансной томо- графии [Tекст] / П. И. Лукьяненок, А. В. Дубровин, Т. К. Гудкова [и др.] // Медицинская визуализация. – 2007. – № 3. – С. 29-36.
• Ahmed S. Outcome of transsphenoidal surgery for acromegaly and its relation-ship to surgical experience [Text] / S. Ahmed, M. Elsheikh, В. С. Х. Page [et al.] / Clinical. Endocrinol. – 1999. – № 50. – Р. 561-567.
• Chanson P. Pituitary tumours: acromegaly [Text] / P. Chanson, S. Salenave, P. Kamenicky [et al.] // Best Pract. Res. Clin. Endocrinol. Metab. – 2009. – Vol. 23, № 5. – Р. 555-574.
• Di Chiro G. The volume of the cella turcica [Text] / G. Di Chiro, K. B. Nelson // Am. J. Radiol. – 1962. – Vol. 87. – P. 989-1008.
• Giustina A. Criteria for Cure of Acromegaly: A Consensus Statement [Text] / A. Giustina, A. Barkan, F. F. Casanueva, F. Cavag- nini // J. Clin. Endocrinol. Metabol. – 2000. – Vol. 85, № 2. – P. 526-529.
• Gong J. Matrix metalloproteinase-9, a potential biological marker in inva sive pituitary adenomas [Text] / J. Gong, Y. Zhao, R. Abdel-Fattah [et al.] // Pituitary. – 2008. – Vol. 11, № l. – P. 37-48.
• Hwa J. Ch. Clinicopathologic Analysis of Pituitary Adenoma – A Single Institute Experience [Text] // J. Ch. Hwa [et al.] / J. Korean Med. Sci. – 2014. – № 29. – P. 405-410.
• Knosp E. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67 [Text] / E. Knosp, K. Kitz,
• Perneczky // Neurosurgery. – 1989. – Vol. 25. – P. 927-930.
• Landis С. A. GTPase inhibiting mutations activate the a-chain of Gs and stimulate adenylate cyclase in human pituitary tumors [Text] / C. A. Landis [et al.] // Nature. – 1989. – Vol. 340. – P. 692-696.
• Melmed S. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline [Text] / S. Melmed, F. F. Casanueva, A. R. Hoffman [et al.] // J. Clin. Endocrinol. Metab. – 2011. – Vol. 96, № 2. – Р. 273-288.
• Scheithauer B. W. Pathobiology of pituitary adenomas and carcinomas [Text] / B. W. Scheithauer [et al.] // Neurosurgery. – 2006. – Vol. 59, № 2. – Р. 341-353.
• Shao S. Clinical features and analysis in 1385 Chinese patients with pituitary adenomas [Text] / S. Shao, X. Li // J. Neurosurg. Sci. – 2013. – Vol. 57, № 3. – Р. 267-75.
• Spada A. Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase [Text] / A. Spada [et al.] // J. Clin. Endocrinol. Metab. – 1990. – Vol. 71. – P. 1421-1426.
• Vallar L. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas [Text] / L. Vallar, A. Spada, G. Giannattasio // Nature. – 1987. – Vol. 330. – P. 566-568.

«Bulletin of problems biology and medicine» Issue 3 part 3 (112), 2014 year, 161-165 pages, index UDK 616. 432:616-006:616. 71-007. 152:616-007. 61:612. 433. 664